Senovac

Senovac has been studied in 1 paper since 2026: none in people yet, 1 in animals; 1 in the past year. The research so far is in animals. The newest paper, May 20, 2026: “Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy”.

Intervention

1 paper studies it2 findingsUpdated

See all 1 papers on senovac

At a glance

The findings reach mice, none yet in people. 1 lab in 1 country.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 1 lab in 1 country
  • Funders: Fourth Military Medical University and 1 more
  • Animals1

What did studies of senovac find?

2

Studies of senovac measured 2 outcomes: atherosclerosis and senescent cells.

Atherosclerosis

downin mice1

1 study
  1. Senovac decreases atherosclerosis in ApoE-/- mouse model of atherosclerosis.

    “effectively cleared plaque senescent cells, attenuated disease progression”

    Animalsin ApoE-/- mouse model of atherosclerosis

    Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

More on Atherosclerosis

Senescent cells

downin mice1

1 study
  1. Senovac decreases senescent cells in ApoE-/- mouse model of atherosclerosis.

    “effectively cleared plaque senescent cells, attenuated disease progression”

    Animalsin ApoE-/- mouse model of atherosclerosis

    Senescent Cell Derived Artificial Vesicle-Based Senolytic Sonovaccine Platform with Augmented Lymph Node Delivery and Antigen Cross-Presentation Efficacy

    Advanced science (Weinheim, Baden-Wurttemberg, Germany)

More on Senescent cells

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 0Apr 2026: 0May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 01 paper in 12 months